全文获取类型
收费全文 | 5156篇 |
免费 | 366篇 |
国内免费 | 48篇 |
专业分类
耳鼻咽喉 | 89篇 |
儿科学 | 147篇 |
妇产科学 | 115篇 |
基础医学 | 755篇 |
口腔科学 | 45篇 |
临床医学 | 512篇 |
内科学 | 1186篇 |
皮肤病学 | 61篇 |
神经病学 | 423篇 |
特种医学 | 241篇 |
外国民族医学 | 4篇 |
外科学 | 961篇 |
综合类 | 39篇 |
一般理论 | 5篇 |
预防医学 | 262篇 |
眼科学 | 82篇 |
药学 | 304篇 |
中国医学 | 7篇 |
肿瘤学 | 332篇 |
出版年
2022年 | 43篇 |
2021年 | 84篇 |
2020年 | 85篇 |
2019年 | 133篇 |
2018年 | 159篇 |
2017年 | 70篇 |
2016年 | 107篇 |
2015年 | 143篇 |
2014年 | 202篇 |
2013年 | 232篇 |
2012年 | 356篇 |
2011年 | 363篇 |
2010年 | 213篇 |
2009年 | 195篇 |
2008年 | 283篇 |
2007年 | 287篇 |
2006年 | 314篇 |
2005年 | 264篇 |
2004年 | 227篇 |
2003年 | 234篇 |
2002年 | 197篇 |
2001年 | 104篇 |
2000年 | 94篇 |
1999年 | 97篇 |
1998年 | 81篇 |
1997年 | 58篇 |
1996年 | 57篇 |
1995年 | 45篇 |
1994年 | 38篇 |
1993年 | 40篇 |
1992年 | 66篇 |
1991年 | 47篇 |
1990年 | 56篇 |
1989年 | 55篇 |
1988年 | 53篇 |
1987年 | 44篇 |
1986年 | 42篇 |
1985年 | 33篇 |
1984年 | 33篇 |
1983年 | 28篇 |
1982年 | 21篇 |
1981年 | 16篇 |
1980年 | 14篇 |
1979年 | 20篇 |
1978年 | 27篇 |
1977年 | 14篇 |
1976年 | 16篇 |
1973年 | 14篇 |
1972年 | 18篇 |
1966年 | 13篇 |
排序方式: 共有5570条查询结果,搜索用时 15 毫秒
51.
S. Filppula S. Yaddanapudi R. Mercier W. Xu S. Pavlopoulos A. Makriyannis 《Chemical biology & drug design》2004,64(6):225-236
Abstract: The cannabinergic system is present in a variety of organs and tissues that perform a wide range of essential physiologic functions making it an inherently important therapeutic target for drug discovery. In order to augment our knowledge regarding the interactions between cannabinoid receptors (CBs) and their ligands, efficient and effective tools are essential for robust expression and purification of these membrane‐bound proteins. In this report, we describe a suitable method for purification of the human cannabinoid receptor 2 (CB2) to a qualitative and quantitative level sufficient for mass spectral analysis. We utilized a baculovirus expression system, incorporating several epitope tags to facilitate purification and to ameliorate the effect the tags have on CB2 expression and function. Expressed protein encoded by a carboxy (C)‐terminal His‐tagged CB2 construct displayed a Bmax value of 9.3 pmol/mg with a KD of 7.30 nm using [3H]CP–55940, a standard cannabinoid radioligand, and was selected for subsequent purification experiments. Western blot analysis of purified membrane protein yielded several forms of CB2, the most abundant being a 41 kDa peptide. A second protein species was observed with an apparent molecular weight of 46 kDa representing a glycosylated form of CB2. In addition, a CB2 homodimer was also identified. The purified receptor was subjected to mass spectroscopic analysis to confirm its identity and purity. Mass spectra corresponding to the intracellular, extracellular and transmembrane domains were obtained. These experiments exemplify the importance of high‐level expression systems when developing membrane‐bound protein purification strategies. This work will aid in the identification of receptor–ligand binding sites, the characterization of molecular features involved in receptor activation, and the elucidation of the CB2 receptor tertiary structure. 相似文献
52.
53.
54.
55.
56.
Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and P-glycoprotein activity in mice. 总被引:1,自引:0,他引:1
Vincent Castagne Laurence Bonhomme-Faivre Saik Urien Makram Ben Reguiga Mireille Soursac Francois Gimenez Robert Farinotti 《Drug metabolism and disposition》2004,32(2):168-171
P-glycoprotein (P-gp) is an ATP-dependent efflux membrane transporter involved in many drug pharmacokinetics in humans. Decreasing its expression could enhance the bioavailability of substrates as digoxin. We have recently found that human recombinant interleukin-2 (rIL2) in vivo decreases P-gp expression in intestine and brain of mice and modifies oral digoxin pharmacokinetics. The aim of the study was to evaluate the involvement of bioavailability in the rIL2 pretreatment effect on digoxin pharmacokinetics by comparing oral and i.v. digoxin pharmacokinetics before and after rIL2 pretreatment (10 microg/kg). We also tried to show the possible effect of a low rIL2 dose (1 microg/kg) pretreatment on oral digoxin pharmacokinetics. First, adult Swiss mice received a single oral or i.v. dose of digoxin (0.03 mg/kg). Two weeks later, the same animals were treated by rIL2 i.p. twice a day (10 microg/kg) for 4 days and received digoxin again at day 5. As well, another group received oral digoxin (0.03 mg/kg) with a 1 microg/kg rIL2 pretreatment. Blood was collected after digoxin administration with and without rIL2 pretreatment. Digoxin pharmacokinetics were described by a one-compartment model. The 10 microg/kg rIL2 pretreatment did not modify i.v. digoxin pharmacokinetics, whereas oral digoxin pharmacokinetics were significantly modified by the 10 microg/kg rIL2 pretreatment and not by the 1 microg/kg rIL2 pretreatment. The decrease of P-gp activity, caused by rIL2 (10 microg/kg), increased digoxin bioavailability. An increase in exposure and intracellular level of drugs is expected from rIL2 pretreatment. 相似文献
57.
Filip Kiekens Ann Debunne Chris Vervaet Lieven Baert Filip Vanhoutte Ivo Van Assche Francois Menard Jean Paul Remon 《European journal of pharmaceutical sciences》2004,22(2-3):117-126
The volume reduction behaviour of powders has been quantified by means of the 'in-die' yield pressure (YP) using Heckel analysis. However, because different YPs are reported for the same material, the experimental conditions influencing this material-constant were investigated. Silicified microcrystalline cellulose was compressed into flat-faced and convex tablets using a compaction simulator instrumented with load and displacement transducers. During compression, upper and lower punch force and displacement data were recorded and corrected for punch deformation. A symmetrical triangle wave compression profile was used and the instantaneous punch velocity was kept constant (5mm/s). Individual tablet height and weight were used for Heckel analysis. The influence of the 'effective compression pressure' (P(EFF)) (ranging from 10 to 350 MPa), punch diameter (PD) (4, 9.5 and 12 mm) and filling depth (FD) (4.5, 7.5 and 10.5mm) on YP was statistically evaluated using Response Surface Modelling software. A quadratic surface response equation, describing the relationship between P(EFF), PD, FD and YP, was proposed for concave (Adj R(2): 0.8424; S.D.: 14.60 MPa) and flat-faced (Adj R(2): 0.8409; S.D.: 4.49 MPa) punches. YP and tensile strength were mainly determined by P(EFF), irrespective of punch curvature. FD and PD had only a minor influence on the YP, although more pronounced for the concave punches. The method used resulted in reproducible P(EFF) and tensile strength values and the flat-faced tablets showed less weight variation. Flat-faced punches are preferred over punches with a concave surface when investigating the volume reduction behaviour of a powder by means of Heckel analysis and the experimental parameters should be reported. 相似文献
58.
Modabber Milad Talajic Julia C. Mabon Michèle Mercier Mathieu Jabbour Samir Choremis Johanna 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2018,256(12):2385-2390
Graefe's Archive for Clinical and Experimental Ophthalmology - To evaluate whether the preparation of Descemet membrane endothelial keratoplasty (DMEK) grafts into various shapes affect their... 相似文献
59.
60.
AIMS: Nifedipine is believed to be a superior tocolytic agent on the basis of efficacy and side-effect profile, but was never prospectively evaluated in a placebo-controlled randomized clinical trial (RCT). In our study, we sought to identify limitations in participation for a would-be RCT comparing nifedipine to placebo. METHODS: A prospective feasibility study was conducted at Ste-Justine Hospital, a tertiary care center, on women between 24 and 34 weeks' gestation, presenting to the labor and delivery room with obstetrical complaints. Patient information was collected and would-be participants were identified on the basis of pre-established clinical and ultrasound criteria as well as on willingness to participate, as determined by the study research nurse. RESULTS: During a 6-month period, 483 women presenting with signs and symptoms of preterm labor (PTL) were eligible for further evaluation. A total of 321 (66.5%) women were excluded for obstetrical and medical reasons whereas 125 (25.9%) did not meet strict inclusion criteria (cervical length <25 mm or positive fetal fibronectin). When using strict criteria, only 37 women (7.6%) were found to be eligible for study participation. Subject willingness to participate as assessed by the research nurse was 50%. CONCLUSIONS: If adhering to strict inclusion/exclusion criteria, the feasibility of an appropriately sampled RCT testing tocolytic therapy against a placebo would require a large concerted multicenter effort to meet sample size demands. 相似文献